The therapeutic challenge of complex diseases requires the use of combination therapies to target the distinct mechanisms and pathways involved. Such complex diseases will benefit from the design of computational models adopting a systems perspective to integrate the knowledge generated by 'omics technologies and clinical data. Multiple Sclerosis is a prototypic debilitating complex disease in which an autoimmune attack is launched against the brain, resulting in significant disability [1,2]. Current therapies for MS are far from effective and target only part of the immune response. MS is the second cause of disability in young people in the EU, and it imposes a significant social and health burden to EU citizens and governments [3,4].
Hence, the need to develop combination therapies with good safety profiles that better control this condition, the main aim of CombiMS. By understanding how current MS therapies work in biological networks and taking advantage of novel compounds, more effective combination therapies will be designed for MS. Indeed, the tools developed will be applicable to other immune and complex diseases to improve their therapeutic options in the future. The data for the modelling process will be generated from biological and clinical samples, and the predictions about combination therapies from the computational models tested using in vitro and animal models of MS. Given the limitations of animal models in translational research, we shall focus on studying the phosphoproteome in samples from individuals with MS (PBMC) using xMAP technology. The phosphoproteome has been identified as a system likely to be affected in MS and the novel therapeutic compounds that will be tested are known to act through signalling pathways involving receptor tyrosine kinases. The mechanistic modelling will be extended to the different levels of the response to therapy by analyzing biological networks integrating gene and protein networks, with drugs, their effects and side-effects. As well as developing new combination therapies for MS, CombMS will provide proof of concept of the useful short term results that a systems biology drug discovery approach can provide.
The research project "A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis"–CombiMs- was launched in January 2013 by a consortium of eight institutions –academic and industrial- from five European countries. With a duration of two years, this Collaborative Project is supported by funding under the Seventh Framework Programme of the European Union.
 Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-1517
 Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61-76
 M. Comabella, S.J. Khoury, Immunopathogenesis of multiple sclerosis, Clin. Immunol. (2011)
 Olesen J, Leonardi M. The burden of brain diseases in Europe. Eur.J.Neurol. 2003;10:471-477
Albert G. Zamora, Coordinator
Bionure Farma S.L.
Dalmases, 27, Local 1 08017 Barcelona
CombiMS welcomes any questions or comments you might have.
Your questions are important to us, and we will reply as soon as possible.